School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia.
Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.
Int J Mol Sci. 2020 Mar 4;21(5):1768. doi: 10.3390/ijms21051768.
The DNA damage response enables cells to survive and maintain genome integrity. RAD52 is a DNA-binding protein involved in the homologous recombination in DNA repair, and is important for the maintenance of tumour genome integrity. We investigated possible correlations between RAD52 expression and cancer survival and response to preoperative radiotherapy. RAD52 expression was examined in tumour samples from 179 patients who underwent surgery for rectal cancer, including a sub-cohort of 40 patients who were treated with neoadjuvant therapy. A high score for RAD52 expression in the tumour centre was significantly associated with worse disease-free survival (DFS; = 0.045). In contrast, reduced RAD52 expression in tumour centre samples from patients treated with neoadjuvant therapy ( = 40) significantly correlated with poor DFS ( = 0.025) and overall survival (OS; = 0.048). Our results suggested that RAD52 may have clinical value as a prognostic marker of tumour response to neoadjuvant radiation and both disease-free status and overall survival in patients with rectal cancer.
DNA 损伤反应使细胞能够存活并维持基因组完整性。RAD52 是一种 DNA 结合蛋白，参与 DNA 修复中的同源重组，对维持肿瘤基因组完整性很重要。我们研究了 RAD52 表达与癌症生存和对术前放疗反应之间的可能相关性。我们检查了 179 名接受直肠癌手术的患者的肿瘤样本中的 RAD52 表达，其中包括 40 名接受新辅助治疗的患者的亚组。肿瘤中心 RAD52 表达评分较高与无病生存率（DFS；=0.045）显著相关。相反，接受新辅助治疗的患者肿瘤中心样本中 RAD52 表达减少（=40）与较差的 DFS（=0.025）和总生存率（OS；=0.048）显著相关。我们的结果表明，RAD52 可能作为预测肿瘤对新辅助放疗反应和直肠癌患者无病状态和总体生存的预后标志物具有临床价值。
